Investment
Features
FeesSafety
Academy
More
Pluang+

Compare State Street SPDR Bloomberg High Yield Bond ETF (JNK) vs Novartis AG (NVS) Price & Performance

State Street SPDR Bloomberg High Yield Bond ETFTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

State Street SPDR Bloomberg High Yield Bond ETF vs Novartis AG — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $95.88, while Novartis AG trades at $152.65 (market cap $295.37B). The key difference: Novartis AG pays a 3.07% dividend while State Street SPDR Bloomberg High Yield Bond ETF pays none, and Novartis AG is trading nearer its 52-week high, State Street SPDR Bloomberg High Yield Bond ETF nearer its low. Which is the better fit depends on your goals.

JNKNVS
Sector
Fixed IncomeHealth
52-Week High
$98.19$168.62
52-Week Low
$94.66$119.31
Market Cap
$295.37B
Enterprise Value
$336.69B
Dividend Yield
3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

State Street SPDR Bloomberg High Yield Bond ETF

JNK trades at $95.845, up 0.2% today, with a bearish technical outlook indicated by moving averages and ADX signals. Recent news highlights risks from AI-related corporate debt and rising Treasury yields, while dividend payments provide income. The ETF faces headwinds from inflation and geopolitical tensions affecting bond markets.

The outlook is cautious due to credit market risks and Fed uncertainty. Opportunities exist for yield-seeking investors, but volatility from oil prices and rate hikes poses significant risks. Monitoring economic data and corporate credit health is essential for navigating near-term performance.

Novartis AG

Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.

The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About State Street SPDR Bloomberg High Yield Bond ETF

JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.

Read more on JNK

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS